Literature DB >> 10850617

High-performance liquid chromatographic determination of naltrexone in plasma of hemodialysis patients.

K Kambia1, S Bah, T Dine, R Azar, P Odou, B Gressier, M Luyckx, C Brunet, L Ballester, M Cazin, J C Cazin.   

Abstract

A simple, sensitive, selective and reliable reversed-phase high-performance liquid chromatographic (HPLC) method with UV detection is described for the determination of naltrexone in plasma samples. Naltrexone and the internal standard, naloxone, were isolated from plasma either with a liquid-liquid extraction method using ethyl acetate or with a solid-phase extraction method using Sep-Pack C18 cartridge before chromatography. The extracts were dried under a stream of nitrogen and the samples were reconstituted in the mobile phase, then 20 microL were injected on a Waters Symmetry C18 column (5 microm particle size, 4.6 x 150 mm). The mobile phase consisted of 0.06% triethylamine (pH 2.8)-acetonitrile (92:8, v/v) pumped at 1 mL/min. The peak-area ratio versus plasma concentration was linear over the range of 10-500 ng/mL and the detection limit was less than 8 ng/mL. Quantification was by ultra-violet detection at 204 nm. The present method was applied to the determination of the plasma concentration of naltrexone in dialyzed patients. Patients (n = 8) with severe generalized pruritus received 50 mg of naltrexone orally per day for 2 weeks. The variability in the therapeutic response in treated patients required plasma concentration investigations of this opioid antagonist.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10850617     DOI: 10.1002/1099-0801(200005)14:3<151::AID-BMC941>3.0.CO;2-E

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  1 in total

1.  Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis.

Authors:  Nicolas K Kambia; Thierry Dine; Pascal Odou; Salmane Bah; Raymond Azar; Bernard Gressier; Thérèse Dupin-Spriet; Michel Luyckx; Claude Brunet
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Oct-Dec       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.